GE HealthCare and Mayo Clinic Launch MI-BET Study to Advance Personalized Radioligand Therapy for Advanced Prostate Cancer
GE HealthCare and Mayo Clinic have announced the launch of the Molecular Imaging Biomarker-Based End of Therapy (MI-BET) research collaboration, a pioneering clinical study designed to evaluate a more personalized approach to radioligand therapy (RLT) for patients with advanced prostate cancer. The initiative represents another significant milestone in precision oncology and aims to determine whether imaging technologies and biomarker data can help clinicians tailor treatment duration based on each patient’s individual response rather than relying on standardized therapy schedules.
The MI-BET study is one of the first major research initiatives to emerge from the Strategic Radiology Research Alliance established between GE HealthCare and Mayo Clinic in 2023. The alliance was created to accelerate innovation in medical imaging, radiology, and precision medicine by combining Mayo Clinic’s clinical research expertise with GE HealthCare’s advanced imaging technologies and digital healthcare solutions.
By integrating molecular imaging, artificial intelligence-supported software, and biological markers throughout treatment, the collaboration seeks to improve clinical decision-making while advancing more individualized care for patients with advanced prostate cancer.
Moving Beyond Standardized Radioligand Therapy
Radioligand therapy has rapidly become one of the most promising treatment approaches in modern oncology, particularly for advanced prostate cancer. As part of the growing field of theranostics, RLT combines highly targeted diagnostic imaging with radioactive therapeutic agents that selectively identify and destroy cancer cells while minimizing damage to surrounding healthy tissue.
Although radioligand therapy has demonstrated encouraging outcomes in many patients, treatment protocols currently follow relatively standardized schedules. Most individuals receive a predetermined number of therapy cycles regardless of how quickly or effectively their tumors respond during treatment.
Researchers believe that this “one-size-fits-all” approach may not fully account for the biological differences that exist between patients.
The MI-BET trial has been designed to investigate whether treatment decisions can instead be guided by continuous assessments of disease response. Rather than automatically completing every scheduled treatment cycle, clinicians participating in the study will evaluate imaging findings and biomarker data collected throughout therapy to determine whether treatment should continue or be temporarily paused.
This adaptive strategy could allow physicians to individualize care while reducing unnecessary treatment exposure for patients who achieve favorable responses earlier than expected.
Harnessing Molecular Imaging for Precision Care
At the heart of the MI-BET study is the use of advanced molecular imaging technologies capable of monitoring tumor response throughout the course of radioligand therapy.
Researchers will utilize GE HealthCare’s StarGuide SPECT/CT system, an advanced imaging platform designed to deliver highly sensitive molecular imaging while simultaneously providing detailed anatomical information through computed tomography.
The imaging system will work in conjunction with MIM Software’s MIM LesionID Pro, an advanced analytics platform that assists clinicians in identifying, tracking, and quantifying tumor burden over time.
Together, these technologies will enable investigators to evaluate how individual tumors respond after each treatment cycle. Instead of relying solely on conventional clinical assessments, physicians will have access to detailed imaging information that may reveal whether cancer lesions are shrinking, stabilizing, or progressing during therapy.
This continuous monitoring provides a richer understanding of treatment effectiveness and may help support more informed clinical decisions.
Combining Imaging with Biomarkers
Beyond imaging alone, the MI-BET study will integrate blood-based biomarkers and clinical outcome data to develop a more comprehensive picture of each patient’s disease.
Researchers hope that combining molecular imaging findings with biological markers will generate insights capable of predicting treatment response earlier in the therapeutic process.
Blood biomarkers may provide valuable information regarding tumor activity, treatment effectiveness, and disease progression, complementing what physicians observe through imaging studies.
The integration of multiple data sources is expected to help researchers identify predictive markers that indicate whether patients are likely to respond favorably to therapy before significant clinical changes become apparent.
Such predictive tools could eventually allow physicians to personalize treatment strategies from the earliest stages of care.
Exploring Adaptive Treatment Decisions
One of the defining features of the MI-BET trial is its emphasis on adaptive treatment planning.
Instead of administering a fixed number of radioligand therapy cycles, investigators will evaluate whether certain patients can safely pause treatment based on favorable imaging and biomarker results.
The decision to temporarily suspend therapy will depend entirely on each patient’s individual disease response observed throughout the study.
If imaging demonstrates significant tumor reduction and biomarker profiles suggest sustained disease control, clinicians may consider interrupting therapy while continuing close monitoring.
Conversely, patients whose disease remains active or progresses may continue receiving additional treatment according to study protocols.
This individualized approach reflects a broader movement within oncology toward precision medicine, where treatment decisions are increasingly guided by patient-specific biological information rather than standardized protocols.
Advancing Theranostics Research
The MI-BET collaboration also seeks to advance the broader scientific understanding of theranostics.
Theranostics has emerged as one of oncology’s fastest-growing specialties because it combines diagnostic imaging and targeted therapy into a unified treatment strategy.
Diagnostic scans first identify cancer cells expressing specific molecular targets. Those same targets can then be treated using radioactive therapeutic compounds that deliver radiation directly to malignant tissue.
This highly targeted approach offers several potential advantages over conventional cancer treatments, including improved precision, reduced exposure to healthy tissues, and enhanced monitoring of treatment response.
Through MI-BET, researchers hope to identify additional imaging biomarkers capable of supporting future clinical decision-making and improving therapeutic outcomes.
Expanding Patient Access to Advanced Care
In addition to advancing scientific knowledge, the collaboration places significant emphasis on improving access to cutting-edge cancer therapies.
The research team plans to encourage broad patient participation through multiple outreach initiatives, including collaboration with community healthcare providers, patient advocacy organizations, and expanded educational efforts.
The study will also incorporate telemedicine and other digital health solutions that may reduce logistical barriers preventing patients from participating in clinical research.
These efforts are intended to make advanced theranostic research accessible to a more diverse patient population while supporting equitable participation in clinical trials.
Improving access remains particularly important as radioligand therapy becomes increasingly integrated into routine oncology practice.
Strengthening the GE HealthCare–Mayo Clinic Alliance
The MI-BET initiative further strengthens the long-term research partnership established between GE HealthCare and Mayo Clinic.
The Strategic Radiology Research Alliance announced in 2023 was created to accelerate innovation across diagnostic imaging, clinical research, artificial intelligence, digital health technologies, and precision medicine.
By combining Mayo Clinic’s extensive clinical expertise with GE HealthCare’s technological capabilities, both organizations aim to develop new imaging solutions that improve patient care while advancing medical research.
The collaboration also supports the development of next-generation diagnostic tools capable of providing clinicians with increasingly personalized insights into disease progression and therapeutic response.
Investigating Next-Generation Imaging Technology
The MI-BET study will be conducted at Mayo Clinic’s Rochester, Minnesota campus, where investigators will also evaluate GE HealthCare’s next-generation StarGuide GX SPECT/CT system.
Mayo Clinic is the first research center in the United States to investigate the capabilities of this advanced imaging platform.
Researchers will assess whether the new technology can reduce scan times while simultaneously improving the precision of tumor visualization and measurement.
Faster imaging examinations could enhance patient comfort and increase clinical workflow efficiency, while improved image quality may provide clinicians with more accurate assessments of disease response throughout therapy.
The evaluation of StarGuide GX represents another important component of the collaboration’s broader objective to modernize molecular imaging and expand the capabilities of theranostic care.
Supporting the Future of Precision Oncology
As oncology continues moving toward individualized treatment strategies, studies like MI-BET are expected to play an increasingly important role in shaping future standards of care.
Rather than treating all patients according to identical protocols, researchers are seeking evidence that treatment intensity and duration can be tailored based on continuously evolving clinical information.
The integration of advanced imaging, artificial intelligence-driven analytics, biomarker science, and adaptive treatment planning reflects this transformation toward precision oncology.
If successful, findings from the MI-BET collaboration could help establish new approaches for managing radioligand therapy, reducing unnecessary treatment exposure while maintaining therapeutic effectiveness.
The research may also contribute to the identification of predictive biomarkers capable of guiding future clinical decisions, ultimately supporting more personalized cancer care for patients with advanced prostate cancer.
By combining innovative imaging technologies with world-class clinical research, GE HealthCare and Mayo Clinic aim to generate evidence that not only advances theranostics but also improves patient outcomes and expands access to precision medicine. As the study progresses, the insights gained could influence future radioligand therapy protocols and further establish adaptive, data-driven treatment strategies as a cornerstone of modern oncology.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.